Literature DB >> 23921954

Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion.

Vladimir I Chefer1, Cristina M Bäckman, Eduardo D Gigante, Toni S Shippenberg.   

Abstract

Kappa-opioid receptor (KOR) agonists have dysphoric properties in humans and are aversive in rodents. This has been attributed to the activation of KORs within the mesolimbic dopamine (DA) system. However, the role of DA in KOR-mediated aversion and stress remains divisive as recent studies have suggested that activation of KORs on serotonergic neurons may be sufficient to mediate aversive behaviors. To address this question, we used conditional knock-out (KO) mice with KORs deleted on DA neurons (DAT(Cre/wt)/KOR(loxp/loxp), or DATCre-KOR KO). In agreement with previous findings, control mice (DAT(Cre/wt)/KOR(wt/wt) or WT) showed conditioned place aversion (CPA) to the systemically administered KOR agonist U69,593. In contrast, DATCre-KOR KO mice did not exhibit CPA with this same agonist. In addition, in vivo microdialysis showed that systemic U69,593 decreased overflow of DA in the nucleus accumbens (NAc) in WT mice, but had no effect in DATCre-KOR KO mice. Intra- ventral tegmental area (VTA) delivery of KORs using an adeno-associated viral gene construct, resulted in phenotypic rescue of the KOR-mediated NAc DA response and aversive behavior in DATCre-KOR KO animals. These results provide evidence that KORs on VTA DA neurons are necessary to mediate KOR-mediated aversive behavior. Therefore, our data, along with recent findings, suggest that the neuronal mechanisms of KOR-mediated aversive behavior may include both dopaminergic and serotonergic components.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921954      PMCID: PMC3828533          DOI: 10.1038/npp.2013.171

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  39 in total

1.  Drug-induced conditioned place preference and aversion in mice.

Authors:  Christopher L Cunningham; Christina M Gremel; Peter A Groblewski
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

Review 2.  Kappa-opioid ligands in the study and treatment of mood disorders.

Authors:  William A Carlezon; Cécile Béguin; Allison T Knoll; Bruce M Cohen
Journal:  Pharmacol Ther       Date:  2009-06-02       Impact factor: 12.310

3.  Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine.

Authors:  John E Pintar; Toni S Shippenberg; Vladimir I Chefer; Traci Czyzyk; Elizabeth A Bolan; Jose Moron
Journal:  J Neurosci       Date:  2005-05-18       Impact factor: 6.167

4.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

5.  Characterization of a mouse strain expressing Cre recombinase from the 3' untranslated region of the dopamine transporter locus.

Authors:  Cristina M Bäckman; Nasir Malik; Yajun Zhang; Lufei Shan; Alex Grinberg; Barry J Hoffer; Heiner Westphal; Andreas C Tomac
Journal:  Genesis       Date:  2006-08       Impact factor: 2.487

6.  Selective deletion of PTEN in dopamine neurons leads to trophic effects and adaptation of striatal medium spiny projecting neurons.

Authors:  Oscar Diaz-Ruiz; Agustin Zapata; Lufei Shan; YaJun Zhang; Andreas C Tomac; Nasir Malik; Fidel de la Cruz; Cristina M Bäckman
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

7.  Mu opioid receptor modulation of somatodendritic dopamine overflow: GABAergic and glutamatergic mechanisms.

Authors:  V I Chefer; L Denoroy; A Zapata; T S Shippenberg
Journal:  Eur J Neurosci       Date:  2009-07-15       Impact factor: 3.386

8.  Activation of the kappa opioid receptor in the dorsal raphe nucleus mediates the aversive effects of stress and reinstates drug seeking.

Authors:  Benjamin B Land; Michael R Bruchas; Selena Schattauer; William J Giardino; Megumi Aita; Daniel Messinger; Thomas S Hnasko; Richard D Palmiter; Charles Chavkin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-28       Impact factor: 11.205

9.  Quantitative no-net-flux microdialysis permits detection of increases and decreases in dopamine uptake in mouse nucleus accumbens.

Authors:  Vladimir I Chefer; Agustin Zapata; Toni S Shippenberg; Peter M Bungay
Journal:  J Neurosci Methods       Date:  2006-02-08       Impact factor: 2.390

10.  Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex.

Authors:  Elyssa B Margolis; Hagar Lock; Vladimir I Chefer; Toni S Shippenberg; Gregory O Hjelmstad; Howard L Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-13       Impact factor: 11.205

View more
  54 in total

Review 1.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

2.  Kappa opioid agonists reduce oxycodone self-administration in male rhesus monkeys.

Authors:  C Austin Zamarripa; Jennifer E Naylor; Sally L Huskinson; E Andrew Townsend; Thomas E Prisinzano; Kevin B Freeman
Journal:  Psychopharmacology (Berl)       Date:  2020-01-31       Impact factor: 4.530

3.  Effects of kappa opioid receptors on conditioned place aversion and social interaction in males and females.

Authors:  Cindee F Robles; Marissa Z McMackin; Katharine L Campi; Ian E Doig; Elizabeth Y Takahashi; Michael C Pride; Brian C Trainor
Journal:  Behav Brain Res       Date:  2014-01-18       Impact factor: 3.332

4.  Abuse Liability, Anti-Nociceptive, and Discriminative Stimulus Properties of IBNtxA.

Authors:  Ariful Islam; Mohammad Atiqur Rahman; Megan B Brenner; Allamar Moore; Alyssa Kellmyer; Harley M Buechler; Frank DiGiorgio; Vincent R Verchio; Laura McCracken; Mousumi Sumi; Robert Hartley; Joseph R Lizza; Gustavo Moura-Letts; Bradford D Fischer; Thomas M Keck
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-27

Review 5.  Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression.

Authors:  T Chase Francis; Mary Kay Lobo
Journal:  Biol Psychiatry       Date:  2016-09-15       Impact factor: 13.382

6.  Kappa counterconditioning of cocaine cues.

Authors:  John R Mantsch; Robert C Twining
Journal:  Neuropsychopharmacology       Date:  2018-03-06       Impact factor: 7.853

Review 7.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

8.  The effects of morphine, naloxone, and κ opioid manipulation on endocrine functioning and social behavior in monogamous titi monkeys (Callicebus cupreus).

Authors:  B J Ragen; N Maninger; S P Mendoza; K L Bales
Journal:  Neuroscience       Date:  2014-12-06       Impact factor: 3.590

9.  Identification of the Kappa-Opioid Receptor as a Therapeutic Target for Oligodendrocyte Remyelination.

Authors:  Feng Mei; Sonia R Mayoral; Hiroko Nobuta; Fei Wang; Caroline Desponts; Daniel S Lorrain; Lan Xiao; Ari J Green; David Rowitch; Jennifer Whistler; Jonah R Chan
Journal:  J Neurosci       Date:  2016-07-27       Impact factor: 6.167

10.  The Aversive Agent Lithium Chloride Suppresses Phasic Dopamine Release Through Central GLP-1 Receptors.

Authors:  Samantha M Fortin; Elena H Chartoff; Mitchell F Roitman
Journal:  Neuropsychopharmacology       Date:  2015-07-27       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.